Collectively, these findings describe the power of EBNA1 IgM to discriminate RA-positive individuals from individuals with SLE and HCs, which ultimately may contribute to the generation of new and simplified diagnostic assays. This evidence concerns the gene CD40LG and systemic lupus erythematosus.